Related Experiment Videos
Secondary malignancies after hematopoietic stem cell transplantation
Dipak Ghelani1, Rima Saliba, Marcos de Lima
1Department of Blood and Marrow Transplantation of the University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 423, Houston, TX 77030, USA.
Critical Reviews in Oncology/Hematology
|June 28, 2005
Summary
Hematopoietic stem cell transplants offer cures but can lead to secondary cancers. This review examines risk factors for these transplant complications, including intense immunosuppression.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Hematopoietic stem cell transplantation (HSCT) is a curative therapy for various malignant and non-malignant diseases.
- Long-term survivors of HSCT face risks, including secondary malignancies.
- Increased use of alternative donors necessitates more intensive immunosuppression, impacting immune recovery and increasing risks.
Purpose of the Study:
- To review the incidence of secondary malignancies and B-cell post-transplantation lymphoproliferative disorders (PTLD) after HSCT.
- To identify risk factors associated with these HSCT complications.
Main Methods:
- Literature review on HSCT outcomes.
- Analysis of factors contributing to secondary malignancies and PTLD.
Main Results:
- Secondary malignancies are a significant concern for long-term HSCT survivors.
- Factors include treatment protocols, recipient characteristics, and intensity of immunosuppression.
- Use of non-human leukocyte antigen-identical sibling donors is linked to higher PTLD incidence.
Conclusions:
- Understanding risk factors is crucial for mitigating complications after HSCT.
- Strategies to manage immunosuppression and monitor for secondary malignancies are needed.
- Further research into donor selection and immune reconstitution can improve long-term HSCT outcomes.